AMED Amedisys
- 95.500
- +0.950+1.00%
- 95.400
- -0.100-0.10%
Amedisys News
Cantor Fitzgerald: Reiterates Amedisys (AMED.US) rating, adjusted from neutral to neutral, with a target price of $101.00.
Amedisys Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)
Truist Financial Reaffirms Their Hold Rating on Amedisys (AMED)
Amedisys Analyst Ratings
Amedisys Analyst Ratings
RBC Raises Price Target on Amedisys to $100 From $97 to Reflect UnitedHealth Deal Terms, Keeps Outperform Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amedisys (AMED) and Masimo (MASI)
Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG), BridgeBio Pharma (BBIO) and Amedisys (AMED)
Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Amedisys (AMED) and CVS Health (CVS)
Cantor Fitzgerald Maintains Neutral on Amedisys, Raises Price Target to $101
Amedisys Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Hologic (HOLX), Amedisys (AMED) and Addus Homecare (ADUS)
Amedisys Analyst Ratings
Deutsche Bank Adjusts Amedisys Price Target to $101 From $97, Maintains Buy Rating
Credit Suisse Reiterates Neutral on Amedisys, Maintains $101 Price Target
Amedisys Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amedisys (AMED), Atrys Health SA (Frankfurt: DE:A2T) and GlaxoSmithKline (GB:GSK)
Jefferies Downgrades Amedisys to Hold From Buy, Adjusts Price Target to $101 From $98
Analysis
Price Target
No Data
